Navigation Links
Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
Date:4/23/2013

criteria to stop treatment at 24 weeks, 91 percent (QUEST-1) and 86 percent (QUEST-2) of patients achieved SVR12.

"Given the long-term health risks associated with hepatitis C, it's important that physicians and patients have multiple options to treat the disease," said Ira Jacobson , M.D., chief of the Division of Gastroenterology and Hepatology, Vincent Astor Distinguished Professor of Medicine, Weill Cornell Medical College, and attending physician, New York-Presbyterian Hospital/Weill Cornell Medical Center. "The results of these Phase 3 trials suggest that simeprevir could represent an important new treatment option for people living with genotype 1 chronic hepatitis C."

Patients enrolled in QUEST-1 and QUEST-2 were stratified by HCV genotype 1 subtype and IL28B genotype. In QUEST-1, SVR12 rates among patients treated with simeprevir with IL28B genotype variations were 94 percent for the CC allele, 76 percent for the CT allele, and 65 percent for the TT allele. In QUEST-2, SVR12 rates among patients treated with simeprevir with IL28B genotype variations were 96 percent for the CC allele, 80 percent for the CT allele, and 58 percent for the TT allele. Among patients with METAVIR scores F3 and F4, 70 percent of patients treated with simeprevir in QUEST-1 and 66 percent of patients treated with simeprevir in QUEST-2 achieved SVR12. Among patients with METAVIR scores F0 to F2, 83 percent of patients treated with simeprevir in QUEST-1 and 85 percent of patients treated with simeprevir in QUEST-2 achieved SVR12. The METAVIR score is used to quantify the degree of inflammation and fibrosis of the liver and patients are scored on a four-point scale. 

"Patient response rates to hepatitis C therapy can be variable, depending on factors such as viral genotype and subtype, and liver fibrosis. Patients with genotype 1a, IL28B genotype TT and METAVIR scores of F3 and F4 can be particularly c
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
2. Dr. Kevin Foley to Present DiscGenics Recent Findings at the Lumbar Spine Research Societys Annual Meeting
3. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
4. HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
5. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
6. New Findings Offer Systemic Solutions to Address Non-communicable Diseases (NCDs) in Low- and Middle-income Countries
7. Proof of Concept Study Initial Findings
8. French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
9. ENDECE Neural to Present Findings for Remyelination at 2013 Keystone Symposia on Multiple Sclerosis
10. New Findings Link Telehealth-Enabled Care Coordination with Reduced Mortality for Patients with Congestive Heart Failure
11. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... WASHINGTON , Jan. 23, 2015  A new analysis ... Part D 2015 enrollment data shows that 81 percent ... convenient access and extra discounts at certain pharmacies. The ... "Preferred pharmacy plans are now the foundation of ...
(Date:1/23/2015)... /PRNewswire/-- Harwood Feffer LLP ( www.hfesq.com ) is investigating potential ... ("Advaxis" or the "Company") (NASDAQ: ADXS ), ... to shareholders. On January 21, 2015, an ... Advaxis had misrepresented the clinical data for its ADXS-HPV ...
(Date:1/23/2015)... Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT), announced ... trial of Lixte,s lead compound, LB‑100, is being conducted, has ... John S. Kovach , M.D., the founder and President of ... completed at a single site. Accrual of patients, however, was ...
Breaking Medicine Technology:New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3
... 3 CareFusion Corporation (NYSE: CFN ), a leading, ... the spinoff of Cardinal Health,s clinical and medical products businesses, ... host a conference call on Thurs., Nov. 5, 2009 at ... , The company is changing the date of its earnings ...
... (OTC Bulletin Board: CONX), a worldwide developer and marketer ... on Thursday, November 12, 2009, at 4:00 PM EST ... the first quarter ended September 30, 2009, and the ... , Corgenix invites all those interested in hearing management,s ...
Cached Medicine Technology:CareFusion Moves First Quarter Earnings Announcement to November 5 2
(Date:1/22/2015)... (PRWEB) January 22, 2015 For over 20 years, ... Oceanside and Vista area has treated just about every ... personal injury circumstances. And for those same twenty-plus years, the ... of all those injuries with the best possible doctor. ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
(Date:1/22/2015)... Compare-autoinsurance.org has released a new blog post presenting ... auto insurance policy . , Some types of vehicles cannot ... the newly released blog post to see if their vehicle qualifies ... vehicles are some of the cars that cannot be covered by ...
Breaking Medicine News(10 mins):Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... further evidence to suggest that an enzyme secreted by the ... for new drugs to combat the deadly infectious disease. ... G (PknG), as a promising drug target back in 2004. ... is the secret weapon that enables the TB bug, Mycobacterium ...
... More bicycle riding and other lifestyle changes are urgently needed ... health and could also threaten the economy, the World Health ... indirectly to about 77,000 deaths per year in the region, ... is on the health of the people. If the trend ...
... have announced the birth of the first baby to be produced ... then frozen and defrosted for later use. ,The ... or who cannot be administered drugs that help egg maturation in ... around one year old, was born in Canada after work at ...
... advocates called Monday for tougher regulations on tobacco, as ... ways of boosting global efforts to stop smoking. ... Health Organisation (WHO) aims to find ways of harmonising ... advertising and protection from second-hand smoke. ,Hatai ...
... sleeping under insecticide-treated bed nets might protect older children ... transmission originates from adults and children over five years ... and are more attractive to mosquitoes. ,Current ... children and pregnant women in order to achieve over ...
... recognizing familiar smells could be experiencing an early sign of ... ,Scientists already know that the first lesions of the ... of the brain that is home to olfactory senses. ... tested 589 people aged between 54 to 90, and asked ...
Cached Medicine News:Health News:Structure of TB Enzyme Points the Way to New Drugs: Study 2Health News:UN Calls for Pedal Power to Reduce Environmental Damage 2Health News:First Baby Born from Eggs Matured and Frozen in the Lab 2Health News:Tougher Tobacco Rules Urged at Global Anti-smoking Talks 2
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
This agarose provides superior resolution of small PCR fragments and primers at lower concentrations than standard agaroses. A 3% gel clearly resolves a 10 bp ladder, and a 4% gel approaches the reso...
The PK TP System utilizes fixed chicken erythrocytes sensitized with components of the pathogenic T. pallidum (Nichols Strain) to perform a qualitative screening of Treponema pallidum in human serum ...
... donors on the PK7200 Automated Microplate System, ... attached to a gelatin particle for the ... of the CMV assay as compared to ... use of a gelatin particle as the ...
Medicine Products: